Core Insights - The report emphasizes the importance of identifying certainty amid market uncertainties, particularly influenced by geopolitical tensions and oil price fluctuations [1][2] - It highlights the potential for inflationary pressures in the U.S. due to rising oil prices, suggesting a need to monitor "quasi-stagflation" trading logic's impact on the A-share market [1][2] Group 1: Geopolitical and Market Analysis - The geopolitical situation is described as marginally escalating but still manageable, with ongoing negotiations between the U.S. and Iran amidst military tensions [2] - The report suggests that the market sentiment will fluctuate as the geopolitical landscape evolves, indicating a need for strategic asset allocation [2] - It recommends avoiding high valuation sectors with long performance cycles while focusing on sectors with mid-term growth and performance certainty [2] Group 2: Investment Strategy - A balanced investment strategy is proposed, focusing on "broad energy + technology narrowing" as a hedging approach against geopolitical uncertainties [3] - The report outlines a selection of "golden stocks" across various sectors, emphasizing their potential for performance based on earnings forecasts and market conditions [4][11] Group 3: Sector-Specific Recommendations - **Energy Sector**: - Baofeng Energy is highlighted for its leading position in coal-based olefins, with a projected net profit of 170 billion yuan in 2026, benefiting from stable raw material costs and rising oil prices [11][12] - Satellite Chemical is noted for its competitive advantages in light hydrocarbon integration, with expected net profits of 70 billion yuan in 2026 [17][18] - **Machinery Sector**: - Autowei is recognized for its potential recovery in overseas equipment demand, with a focus on solar, semiconductor, and lithium battery sectors [23][24] - Kaige Precision is positioned to benefit from improvements in its core products and new growth opportunities in automated assembly lines [28][29] - **Environmental Sector**: - Longjing Environmental is expected to enhance its financial position through a capital increase and is projected to achieve significant growth in green energy projects [33][34] - **Automotive Sector**: - Yutong Bus is anticipated to leverage overseas demand for new energy buses, with a projected increase in market share and profitability [37][38] - **New Energy Sector**: - CATL is forecasted to maintain strong growth in net profits, driven by rising demand for energy storage and electric vehicle batteries [50][51] - **Construction Materials**: - Dongfang Yuhong is focusing on optimizing its channel structure and expanding into international markets, which is expected to drive growth [56][57] - **Pharmaceutical Sector**: - Zai Lab is highlighted for its promising drug pipeline, with potential for significant market impact upon commercialization [62][63]

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a 12-month target price of 129.46 CNY [4]. Core Insights - The company reported a revenue of 810 million CNY for 2025, representing a year-on-year growth of 52.07%. However, it incurred a net loss of 163 million CNY [2][4]. - The company has entered into a global development and commercialization partnership with AbbVie for ZG006, which is expected to advance overseas clinical progress. AbbVie has obtained exclusive rights for ZG006 outside Greater China, while the company retains rights within Greater China [1][2]. - The company received an upfront payment of 100 million USD in January 2026, with potential milestone payments of up to 67 million USD based on clinical progress, and up to 1.075 billion USD if AbbVie exercises its licensing option [1][2]. Financial Projections - Revenue projections for the company are estimated at 2.05 billion CNY in 2026, 2.09 billion CNY in 2027, and 2.98 billion CNY in 2028. Corresponding net profits are projected to be 665 million CNY, 443 million CNY, and 772 million CNY respectively [2][11]. - The earnings per share (EPS) are expected to be 2.51 CNY in 2026, 1.67 CNY in 2027, and 2.92 CNY in 2028 [2][11]. - The company’s total market capitalization is approximately 25.55 billion CNY [4]. Product Pipeline - The company has a robust pipeline with products such as ZG005 and ZG006 progressing rapidly. Currently marketed products include Donafenib and Jikaxitinib, among others [2][4].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, specifically recommending attention to companies such as Zai Lab, CanSino Biologics, and Deciphera Pharmaceuticals [1]. Core Insights - The T-cell engagers (TCE) are emerging as a significant area in tumor and autoimmune treatment, showcasing breakthrough efficacy in hematological malignancies like multiple myeloma and lymphoma. The clinical application boundaries of TCE are expanding, with ongoing developments in technology and partnerships [4][12]. - The A-share pharmaceutical index has shown a year-to-date decline of -1.38%, while the Hang Seng Biotechnology Index has increased by +2.52%, indicating a relative strength in the biotech sector [9]. - The report highlights specific sub-sectors within the industry, ranking them as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies. It suggests high-elasticity investment in innovative drugs, particularly in small nucleic acid therapies [10][12]. Summary by Sections Industry Performance - The A-share pharmaceutical index has a weekly performance of -1.26% and a year-to-date performance of -1.38%, outperforming the CSI 300 by 2.31% and 1.37% respectively. The chemical pharmaceuticals sector led with a weekly increase of +1.13% [9]. - Notable stock performances include Meinohua (+54.43%), Wanbangde (+40.68%), and Zai Lab (+27.54%) for gains, while Boin Medical (-23.19%), Duorui Pharmaceuticals (-23.18%), and Xiangyu Medical (-21.40%) faced significant declines [9]. TCE Insights - TCE technology is characterized by its ability to connect T cells with tumor cells, enhancing targeted cell killing without the need for major histocompatibility complex (MHC) molecules. This mechanism mimics natural T cell activation processes [17][21]. - The report outlines the evolution of TCE technology, focusing on advancements such as multi-targeting and precise affinity modulation to improve efficacy and reduce toxicity [22][24]. Recommended Companies - From the TCE perspective, the report recommends focusing on Zai Lab, Deciphera Pharmaceuticals, and CanSino Biologics. Other recommendations include companies in various categories such as PD1 PLUS, ADC, small nucleic acids, and traditional Chinese medicine [12][10].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, specifically recommending attention to companies such as Zai Lab, CanSino Biologics, and Deciphera Pharmaceuticals [1]. Core Insights - The T-cell engagers (TCE) are emerging as a significant opportunity in tumor and autoimmune therapies, with ongoing advancements in clinical applications and technology evolution [4][12]. - The report highlights the strong performance of the pharmaceutical sector, with specific sub-sectors like chemical pharmaceuticals showing notable gains [4][9]. - The report suggests a ranking of favorable sub-industries, with innovative drugs at the top, followed by research services, CXO, traditional Chinese medicine, medical devices, and pharmacies [10][12]. Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a year-to-date decline of -1.38%, while the Hang Seng Biotechnology Index has increased by +2.52% [4][9]. - The report notes that the chemical pharmaceutical sector led the gains this week with an increase of +1.13% [4][9]. TCE Insights - TCEs are recognized for their ability to bridge T cells and tumor cells, demonstrating breakthrough efficacy in hematological malignancies [4][16]. - The report outlines the evolving technology directions for TCEs, including multi-targeting and precise affinity modulation to enhance therapeutic effects while minimizing toxicity [20][22]. R&D Progress and Company Dynamics - Recent approvals and advancements include GenSci's new drug for gastric cancer receiving orphan drug status from the FDA, and AstraZeneca's positive results for a combination therapy in advanced non-small cell lung cancer [4][12]. - The report provides a detailed overview of various companies' pipelines and their respective TCE platforms, highlighting Zai Lab, Deciphera Pharmaceuticals, and CanSino Biologics as key players [4][12][24]. Market Performance - The report includes a performance summary of individual stocks, noting significant gains for companies like Meinohua (+54.43%) and Zai Lab (+27.54%) [4][9]. - It also tracks the performance of various pharmaceutical sub-sectors, indicating a strong market interest in innovative drug development [4][9].

Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 161.08 [6][12] Core Insights - The company reported a revenue of RMB 810 million for 2025, representing a year-on-year increase of 52.1%. The net profit attributable to shareholders was a loss of RMB 163 million, with a non-GAAP net profit loss of RMB 198 million. The fourth quarter of 2025 saw a revenue of RMB 217 million, up 45.8% year-on-year, aligning with the preliminary performance report [1][4] - The company has four innovative drugs already launched in the domestic market, entering a rapid growth phase. The sales personnel count has exceeded 400, and the drugs include Donafenib, Recombination Human Thrombin, JAK inhibitor Gicaxitinib, and Injection Thyroid-Stimulating Hormone β [2][3] - The company is focusing on its pipeline drugs ZG006 and ZG005, with multiple catalysts expected in 2026. ZG006 is anticipated to achieve domestic sales peak of over RMB 4 billion and an overseas peak of nearly USD 6 billion. ZG005 is expected to disclose Phase II data in China in the first half of 2026 [3][4] Financial Forecast and Valuation - Revenue projections for 2026-2028 are RMB 1.861 billion, RMB 2.008 billion, and RMB 2.109 billion, respectively. The net profit attributable to shareholders is forecasted to be RMB 539 million, RMB 475 million, and RMB 279 million for the same period [4][10] - The DCF valuation method estimates the company's market value at RMB 42.639 billion, with a target price of RMB 161.08, maintaining a WACC of 9.7% and a perpetual growth rate of 0% [4][12]

Group 1: Executive Changes - Shareholder ZELIN SHENG plans to reduce holdings by up to 273,907 shares (0.1035% of total share capital) [1] - Shareholder Ningbo Zeao intends to reduce holdings by up to 2,475,090 shares (0.9350% of total share capital) [1] Group 2: Contract Developments - Zai Lab has reached a global development and commercialization agreement with AbbVie for the drug ZG006, granting AbbVie exclusive rights outside Greater China [2] - Zai Lab has received an upfront payment of $100 million and may receive up to $60 million in near-term milestone payments and $1.075 billion in future milestone payments [2] - Clinical trial data for ZG006 shows an objective response rate (ORR) of 53.3% and a median progression-free survival (mPFS) of 7.03 months in the II phase dose optimization trial for small cell lung cancer and neuroendocrine cancer [2] Group 3: Product Development Progress - The injectable ZG005 has confirmed an ORR of 40.9% and a disease control rate (DCR) of 68.2% in II phase clinical trials for cervical cancer [3] - Several candidate drugs, including ZGGS18 and ZGGS34, have entered phase I clinical trials in China and the U.S. [3] Group 4: Financial Performance - The company expects revenue for 2026 to be between 796 million and 829 million yuan, representing a year-on-year growth of 49.45% to 55.55% [4] - This growth is primarily driven by the increase in sales of recombinant human thrombin and the commercialization of Jikaxitinib [4]

2026年2月13日，泽璟制药披露接待调研公告，公司于2月2日至2月10日接待淡水泉、农银汇理、安信基 金、华安基金、建信资产、平安基金等28家机构调研。 调研情况显示，泽璟制药与艾伯维就ZG006达成全球开发及商业化战略合作与许可选择权协议，艾伯维 获大中华区以外地区独家权利，泽璟保留区内权利；泽璟已收到1亿美元首付款，还可获最高6000万美 元近期里程碑及许可选择付款，若选择权行使另有最高10．75亿美元里程碑付款和高个位数到中双位数 阶梯特许权使用费。ZG006正推进单药及联合用药治疗小细胞肺癌、神经内分泌癌等临床试验，包括关 键及III期试验；在晚期小细胞肺癌三线及以上II期剂量优化试验中，10mg每两周一次组确认ORR为53． 3％、mPFS达7．03个月，6个月及12个月OS率分别为83．2％及69．1％；治疗神经内分泌癌推荐剂量 组全人群确认ORR38．5％，DLL3阳性患者达66．7％。 注射用ZG005正推进单药及联合用药治疗肝癌、神经内分泌癌、宫颈癌等试验；二线及以上宫颈癌 20mg／kg Q3W方案确认ORR40．9％、DCR68．2％、mPFS超11个月，联合方案一线宫颈癌及早期肝 癌 ...

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, with a focus on AI-enabled strategic upgrades in pharmaceutical manufacturing [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a 5.6% increase from December 29, 2025, to January 9, 2026, outperforming the Wind All A index (4.76%) and the CSI 300 index (2.18%). Key segments leading this growth include hospitals (12.95%), medical research outsourcing (9.25%), and medical devices (7.96%) [2][7]. - The report highlights the rapid development of AI in healthcare, emphasizing the government's initiative to foster AI in drug development, supply chain management, surgical robotics, and intelligent diagnostic systems by 2027. This initiative aims to cultivate 2-3 leading ecological enterprises and a number of specialized companies [2][11]. - The upcoming JPM Healthcare Conference from January 12 to 15, 2026, is expected to boost the sentiment in the innovative drug sector, with over 500 listed companies and thousands of startups participating [2][11]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 5.6% during the last interval, with hospitals, medical research outsourcing, and medical devices leading the gains. Notably, the stock of Sanbo Brain Science surged by 63.53%, while *ST Changyao saw a decline of 44.9% [7][10]. - The report provides detailed performance metrics for various sub-sectors, with hospitals showing a 12.95% increase, medical research outsourcing at 9.25%, and medical devices at 7.96% [8][9]. Industry News and Key Company Announcements - On January 7, eight departments jointly issued the "AI + Manufacturing" action plan, marking AI drug development and medical supply chain intelligence as national priorities [11]. - Notable company announcements include: - Yilian Bio's exclusive licensing agreement with Roche for the YL201 project, which includes a $570 million upfront payment [11]. - Merck's discussions to acquire Revolution Medicines for $28 billion to $32 billion [11]. - Structure Therapeutics' agreement with Roche and Genentech for a non-exclusive patent license, resulting in a $100 million upfront payment [11][12]. - Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion [14].

Core Viewpoint - On December 31, the company announced a deep global collaboration with AbbVie regarding ZG006, with an upfront payment of $100 million and a total deal value of $1.235 billion. The initial clinical data presented at the ESMO Asia conference showed excellent clinical response rates and good durability in SCLC indications, indicating that this collaboration may accelerate ZG006's advancement in overseas oncology indications and maximize the value of the product pipeline, suggesting a promising future for the company [1][3]. Group 1: Collaboration Details - The company has entered into a global strategic collaboration and licensing option agreement with AbbVie for the development and commercialization rights of ZG006, receiving an upfront payment of $100 million, with potential milestone payments based on clinical progress and licensing options totaling up to $60 million. If AbbVie exercises the licensing option, the company could receive up to $1.075 billion in milestone payments [2][3]. Group 2: Clinical Data and Product Pipeline - ZG006 has shown promising early clinical data in small cell lung cancer (SCLC) at the ESMO Asia conference, with overall response rates (ORR) of 60.0% and 66.7% for the 10 mg Q2W and 30 mg Q2W groups, respectively. The confirmed response rates were 53.3% and 56.7%, with disease control rates (DCR) of 73.3% for both groups. The median progression-free survival (mPFS) was 7.03 months and 5.59 months, while the median duration of response (mDoR) rates at 6 months were 71.8% and 69.5% [4]. Group 3: Commercialization Progress - The company has made breakthroughs in commercialization, with the JAK inhibitor, Jika Xini, expected to be approved by the National Medical Products Administration in May 2025, becoming the first domestically approved JAK inhibitor for treating high-risk myelofibrosis. The product has shown rapid sales growth since its launch in June and has been included in the CSCO guidelines [5]. - The recombinant human thrombin injection is set to launch in 2024, with significant efficacy demonstrated in clinical trials, and is expected to become a core growth driver for revenue [5]. Group 4: Future Catalysts - The company has a clear timeline for key catalysts in 2026, including the continued rollout of insurance policies for the recombinant thrombin and Jika Xini, which are expected to drive sales growth. Additionally, further clinical data for ZG005 and ZG006 is anticipated, along with the ongoing collaboration with AbbVie to advance overseas clinical trials [8]. Group 5: Financial Projections - The company’s revenue projections for 2025-2027 are estimated at 712 million, 1.54 billion, and 2.5 billion yuan, with net profits of -127 million, -77 million, and 147 million yuan, respectively, maintaining a "buy" rating [9].

Core Viewpoint - The innovative drug sector has seen a resurgence, with significant stock price increases following announcements related to brain-computer interface technology and major collaborations in the pharmaceutical industry. Group 1: Market Activity - The innovative drug sector experienced a notable rebound, with the Hong Kong innovative drug ETF rising over 5% after nearly four months of decline [1] - Key stocks such as Zai Lab, Innovent Biologics, and BeiGene saw substantial gains [1] Group 2: Company Collaborations - Yingke Intelligent announced a research collaboration with Servier, valued at $888 million [2] - Zai Lab entered a business development agreement with AbbVie for its CD3×DLL3 trispecific antibody, ZG006, which includes an upfront payment of $100 million and potential milestone payments exceeding $1.1 billion [2][18] Group 3: Company Profile - Zai Lab, founded in 2009 and headquartered in Kunshan, Jiangsu, has three products on the market and focuses on oncology, autoimmune diseases, and hematology [6][10] - The company has a robust pipeline with 11 candidate drugs, including ZG006, which has received breakthrough therapy designation from the National Medical Products Administration in China [16][22] Group 4: Financial Performance - Zai Lab reported revenues of RMB 3.2 billion, RMB 3.84 billion, RMB 5.32 billion, and RMB 5.93 billion for the years 2022, 2023, 2024, and the first nine months of 2025, respectively [23][28] - Despite generating revenue, the company has incurred cumulative losses of RMB 1.027 billion due to high R&D and sales expenses [23][31] Group 5: R&D Pipeline - Zai Lab's R&D pipeline includes several promising candidates, such as ZG005, which targets PD-1/TIGIT and has shown a 40.9% objective response rate in clinical trials [19][22] - The company is advancing multiple candidates through various clinical trial phases, with a focus on innovative therapies for difficult-to-treat cancers [21][22]